MétaCan
Menu
Back to cohort
Record W4409578902 · doi:10.1038/s41408-025-01288-8

Comment on: “Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study” by Busque et al.

2025· letter· en· W4409578902 on OpenAlexaboutno aff
Ahmet Emre Eşkazan

Bibliographic record

VenueBlood Cancer Journal · 2025
Typeletter
Languageen
FieldMedicine
TopicChronic Myeloid Leukemia Treatments
Canadian institutionsnot available
Fundersnot available
KeywordsAffect (linguistics)MedicineProspective cohort studyIntensive care medicineInternal medicinePsychology

Abstract

fetched live from OpenAlex

I have read with great interest the study by Busque et al. [ 1 ], in which the authors evaluated the real-world data on switching patterns of tyrosine kinase inhibitors (TKIs) among a large population of chronic myeloid leukemia (CML) patients in Quebec, Canada. This study is very valuable since data on this topic is still limited in the literature, however, there still some points that need to be further underlined. The study reports that nearly half of the patients were switched to second-line TKI therapy with a median follow-up of approximately 6 years. The most common reason for switching was TKI-associated toxicities [ 1 ]. In the observational SIMPLICITY study, the proportion of patients with a TKI switch was lower than that observed in the study of Busque and colleagues, with the percentages of patients who were switched of an alternative TKI for the first and second years of therapy of 17.8 and 9.5%, respectively [ 2 ]. The update of the same study among European patients showed that, with a median follow-up of 5 years, 25% of patients were switched to second-line TKI therapy [ 3 ]. Similarly, intolerance was the most common reason for switching in the SIMPLICITY study. In the UK TARGET CML study, with a median follow-up of nearly 3 years, 44% of the patients were switched from first-line TKI [ 4 ], which was comparable to that of the Quebec registry [ 1 ]. In this study, resistance was the most common reason for switching, observed in 65% of the patients [ 4 ]. In patients with CML experiencing grade 4 or persisting grade 3 adverse events (AEs) under TKIs, the recommendation is to switch to an alternative treatment [ 5 , 6 ]. As the distribution of toxicity grades were not shared in the study of Busque et al. [ 1 ], maybe not all patients with a TKI switch due to intolerance had grade ≥3 AE. Generic TKIs are now globally available [ 7 , 8 ], and the rates of toxicities may differ between generics and the original molecule as well as between different generics [ 7 , 9 ]. In a previously published study also coming from Quebec, Canada, it was shown that switching to another TKI was higher in patients receiving generic imatinib when compared to those with branded imatinib and intolerance was the main reason for this higher non-persistence [ 10 ]. There was no data on the use of generics in the study of Busque et al. [ 1 ], and it would be interesting to see this information, together with the comparative data between generics and branded TKIs regarding rates of switching and other outcomes.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesMeta-epidemiology (narrow), Research integrity
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: Not applicable
GenreCandidate signal: Commentary · Consensus signal: Commentary
Teacher disagreement score0.204
Threshold uncertainty score1.000

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0010.006
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.013
GPT teacher head0.300
Teacher spread0.286 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

Study designNot applicable
Domainnot available
GenreCommentary

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations1
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueBlood Cancer JournalSame topicChronic Myeloid Leukemia TreatmentsFrench-language works237,207